Back to Search
Start Over
A case of secondary adrenocortical insufficiency due to isolated adrenocorticotropic hormone deficiency with empty sella syndrome after pembrolizumab treatment in a patient with metastatic renal pelvic cancer
- Source :
- Urology Case Reports, Vol 39, Iss, Pp 101766-(2021), Urology Case Reports
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- Pembrolizumab, an anti-programmed death-1 specific monoclonal antibody is a second-line treatment for metastatic urothelial carcinoma. Physicians should be aware of adverse immune-related events associated with the use of immune checkpoint inhibitors, particularly adrenocortical insufficiency, which poses a risk of death. We report a case of secondary adrenocortical insufficiency due to isolated adrenocorticotropic hormone deficiency with empty sella syndrome after pembrolizumab treatment in a patient with metastatic renal pelvic cancer. Fortunately, a therapeutic effect was observed 4 months after discontinuation of pembrolizumab, and a durable antitumor response has persisted for 5 months.
- Subjects :
- medicine.medical_specialty
Metastatic Urothelial Carcinoma
business.industry
Urology
Therapeutic effect
Empty sella syndrome
Cancer
Pembrolizumab
medicine.disease
Gastroenterology
Diseases of the genitourinary system. Urology
Discontinuation
Oncology
Immune-related adverse events
Internal medicine
Isolated adrenocorticotropic hormone deficiency
Medicine
RC870-923
business
Adrenocorticotropic hormone deficiency
Adrenocortical Insufficiency
Adrenocortical insufficiency
Subjects
Details
- Language :
- English
- ISSN :
- 22144420
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- Urology Case Reports
- Accession number :
- edsair.doi.dedup.....bc3d6bc4e920b12d4dc775f6fc6b30ac